Aclaris Therapeutics (NASDAQ:ACRS) Rating Reiterated by Cantor Fitzgerald

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $38.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 411.44% from the stock’s current price.

A number of other equities research analysts also recently commented on ACRS. StockNews.com began coverage on shares of Aclaris Therapeutics in a report on Thursday, August 17th. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $43.00 target price on shares of Aclaris Therapeutics in a report on Tuesday. Finally, Stifel Nicolaus lifted their price target on Aclaris Therapeutics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, September 14th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, Aclaris Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $30.20.

Aclaris Therapeutics Stock Performance

Aclaris Therapeutics stock remained flat at $7.43 during mid-day trading on Tuesday. The company’s stock had a trading volume of 36,614 shares, compared to its average volume of 817,000. The firm has a market cap of $525.97 million, a price-to-earnings ratio of -4.80 and a beta of 0.65. Aclaris Therapeutics has a one year low of $5.77 and a one year high of $18.96. The firm’s 50-day moving average is $8.66 and its two-hundred day moving average is $8.85.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.03. The business had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.90 million. Aclaris Therapeutics had a negative return on equity of 54.43% and a negative net margin of 337.90%. The company’s revenue was up 26.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. As a group, equities research analysts predict that Aclaris Therapeutics will post -1.82 EPS for the current fiscal year.

Insider Activity

In other Aclaris Therapeutics news, insider Joseph Monahan sold 6,000 shares of Aclaris Therapeutics stock in a transaction on Monday, August 21st. The shares were sold at an average price of $7.32, for a total transaction of $43,920.00. Following the sale, the insider now owns 135,724 shares of the company’s stock, valued at approximately $993,499.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Aclaris Therapeutics news, insider James Loerop acquired 14,705 shares of the business’s stock in a transaction on Monday, August 28th. The stock was bought at an average price of $6.80 per share, for a total transaction of $99,994.00. Following the acquisition, the insider now owns 21,688 shares in the company, valued at $147,478.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Monahan sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $7.32, for a total transaction of $43,920.00. Following the completion of the transaction, the insider now directly owns 135,724 shares in the company, valued at $993,499.68. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. UBS Group AG increased its holdings in shares of Aclaris Therapeutics by 41.4% during the 2nd quarter. UBS Group AG now owns 2,406 shares of the biotechnology company’s stock worth $34,000 after buying an additional 704 shares during the last quarter. Royal Bank of Canada lifted its position in Aclaris Therapeutics by 31.6% in the second quarter. Royal Bank of Canada now owns 5,970 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 1,435 shares during the last quarter. Point72 Middle East FZE purchased a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $75,000. Corton Capital Inc. acquired a new position in shares of Aclaris Therapeutics in the 1st quarter worth approximately $84,000. Finally, State of Wyoming purchased a new position in shares of Aclaris Therapeutics during the 4th quarter worth approximately $87,000.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.